PL2279008T3 - Kompozycje farmaceutyczne paklitakselu, analogów paklitakselu lub koniugatów paklitakselu oraz powiązane sposoby wytwarzania i zastosowanie - Google Patents

Kompozycje farmaceutyczne paklitakselu, analogów paklitakselu lub koniugatów paklitakselu oraz powiązane sposoby wytwarzania i zastosowanie

Info

Publication number
PL2279008T3
PL2279008T3 PL09733078T PL09733078T PL2279008T3 PL 2279008 T3 PL2279008 T3 PL 2279008T3 PL 09733078 T PL09733078 T PL 09733078T PL 09733078 T PL09733078 T PL 09733078T PL 2279008 T3 PL2279008 T3 PL 2279008T3
Authority
PL
Poland
Prior art keywords
paclitaxel
preparation
pharmaceutical compositions
conjugates
related methods
Prior art date
Application number
PL09733078T
Other languages
English (en)
Inventor
Michel Demeule
Christian Che
Anthony Regina
Richard Beliveau
Catherine Gagnon
Jean-Paul Castaigne
Reinhard Gabathuler
Original Assignee
Angiochem Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc. filed Critical Angiochem Inc.
Publication of PL2279008T3 publication Critical patent/PL2279008T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09733078T 2008-04-18 2009-04-20 Kompozycje farmaceutyczne paklitakselu, analogów paklitakselu lub koniugatów paklitakselu oraz powiązane sposoby wytwarzania i zastosowanie PL2279008T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12467708P 2008-04-18 2008-04-18
PCT/CA2009/000542 WO2009127072A1 (en) 2008-04-18 2009-04-20 Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
EP09733078.1A EP2279008B1 (en) 2008-04-18 2009-04-20 Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use

Publications (1)

Publication Number Publication Date
PL2279008T3 true PL2279008T3 (pl) 2020-03-31

Family

ID=41198750

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09733078T PL2279008T3 (pl) 2008-04-18 2009-04-20 Kompozycje farmaceutyczne paklitakselu, analogów paklitakselu lub koniugatów paklitakselu oraz powiązane sposoby wytwarzania i zastosowanie

Country Status (17)

Country Link
US (1) US8710013B2 (pl)
EP (1) EP2279008B1 (pl)
JP (2) JP5860698B2 (pl)
CN (1) CN102026667B (pl)
AU (1) AU2009238187B2 (pl)
BR (1) BRPI0910557A2 (pl)
CA (1) CA2721019C (pl)
DK (1) DK2279008T3 (pl)
ES (1) ES2721148T3 (pl)
HK (1) HK1154795A1 (pl)
MX (1) MX355683B (pl)
PL (1) PL2279008T3 (pl)
PT (1) PT2279008T (pl)
RU (1) RU2518240C2 (pl)
TR (1) TR201905480T4 (pl)
WO (1) WO2009127072A1 (pl)
ZA (1) ZA201007170B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516056C (en) 2003-01-06 2012-05-29 Angiochem Inc. Aprotinin and analogs as carriers across the blood-brain barrier
BRPI0520032A2 (pt) 2005-02-18 2009-04-14 Angiochem Inc moléculas para transportar um composto através da barreira hematoencefálica
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
BRPI0613005A8 (pt) 2005-07-15 2017-12-26 Angiochem Inc uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos.
US8487072B2 (en) 2006-10-19 2013-07-16 Angiochem Inc. Compounds for stimulating P-glycoprotein function and uses thereof
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
JP2012512185A (ja) 2008-12-17 2012-05-31 アンジオケム インコーポレーテッド 膜1型マトリックス金属タンパク質阻害剤およびその使用
MX2011011023A (es) 2009-04-20 2012-01-20 Angiochem Inc Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2.
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
CN109745287A (zh) 2010-05-03 2019-05-14 帝国制药美国公司 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
WO2013043864A1 (en) * 2011-09-23 2013-03-28 The Board Of Regents Of The University Of Texas System Compositions and methods related to endothelial targeting
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN105585614B (zh) * 2014-10-24 2019-06-07 中国科学技术大学 用于淀粉样蛋白显像的血管肽及其衍生物
WO2016149162A1 (en) * 2015-03-16 2016-09-22 Meridian Lab Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use
JP6823055B2 (ja) * 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
EP3453390B1 (en) 2016-05-06 2024-02-14 Biodynamic Research Foundation Polymerized drug-containing pharmaceutical composition
US20210186972A1 (en) * 2018-05-15 2021-06-24 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis
WO2020081148A1 (en) * 2018-10-16 2020-04-23 US Nano Food & Drug INC Intratumor injection formulation
CN110227086A (zh) * 2019-07-13 2019-09-13 高天荣 一种用人工种植红豆杉制备口服广普抗癌药的方法
MX2022010387A (es) 2020-04-13 2022-09-05 US Nano Food & Drug INC Formulacion basica para inyeccion quimioterapeutica intratumoral.
CN111671759A (zh) * 2020-07-15 2020-09-18 五邑大学 一种协同抗胰腺癌干细胞的药物组合
CN113406015B (zh) * 2021-05-31 2023-01-13 内蒙古师范大学 一种近岸和内陆水域水体的透明度计算方法和系统
WO2024178236A1 (en) * 2023-02-22 2024-08-29 N1 Life, Inc. Taxol conjugate compounds and pharmaceutical compositions thereof

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US4904768A (en) * 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5028697A (en) * 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de) 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en) * 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6495513B1 (en) * 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US5955444A (en) * 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en) * 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
CA2145517A1 (en) 1992-09-25 1994-04-14 Ignace Lasters Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia - tissue factor complex
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
WO1994019692A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
CA2247888A1 (en) * 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
JP2001503396A (ja) * 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CA2283474A1 (en) 1997-03-04 1998-09-11 Bio-Technology General Corp. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
GB9705903D0 (en) 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
ES2210761T3 (es) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6093692A (en) * 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en) * 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
AU768027B2 (en) * 1999-02-24 2003-11-27 Uab Research Foundation, The Taxane derivatives for targeted therapy of cancer
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
DK1214292T3 (da) 1999-09-24 2007-10-15 Genentech Inc Tyrosinderivater
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE19953696A1 (de) 1999-11-09 2001-05-10 Alexander Cherkasky Selektive proteolytische Synzyme (SPS)
WO2002043765A2 (en) 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
JP2004528309A (ja) * 2001-03-23 2004-09-16 ナプロ バイオセラピューティクス,インコーポレイテッド 癌治療用分子複合体
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
ATE445838T1 (de) * 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US7192921B2 (en) * 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
ATE365213T1 (de) * 2002-02-07 2007-07-15 Yissum Res Dev Co Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern
KR100608558B1 (ko) 2002-03-29 2006-08-03 크레아젠 주식회사 세포질 잔류성 세포막 투과 펩타이드 및 이의 용도
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US7319090B2 (en) 2002-11-27 2008-01-15 University Of North Carolina At Chapel Hill Methods of treating cerebral ischemia
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
CA2516056C (en) * 2003-01-06 2012-05-29 Angiochem Inc. Aprotinin and analogs as carriers across the blood-brain barrier
US20040162284A1 (en) 2003-02-19 2004-08-19 Harris Herbert W. Method of lowering body temperature with (S) tofisopam
CA2520655A1 (en) 2003-04-08 2004-11-04 Biotempt, B.V. Compositions for mucosal and oral administration comprising hcg fragments
CN104383542B (zh) * 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
JP4597976B2 (ja) * 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾iRNA剤
CR20120384A (es) * 2003-05-14 2016-12-02 Immunogen Inc Composición de farmaco conjugado
AU2003286870A1 (en) * 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005002515A2 (en) 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
KR20060036476A (ko) 2003-08-08 2006-04-28 가부시키가이샤 티슈 타겟팅 쟈판 뇌 이동 활성을 가지는 폴리펩티드 및 그 이용
WO2005021579A2 (en) 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Epo mimetic peptides and fusion proteins
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
US20050058702A1 (en) * 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
BRPI0512396A (pt) 2004-07-21 2008-03-11 Ambrx Inc polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
MX2007001180A (es) * 2004-07-26 2007-04-13 Asterion Ltd Enlazantes.
EP1799826B1 (en) * 2004-09-29 2009-08-12 Children's Memorial Hospital siRNA-MEDIATED GENE SILENCING OF ALPHA SYNUCLEIN
US9002652B1 (en) 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
BRPI0520032A2 (pt) 2005-02-18 2009-04-14 Angiochem Inc moléculas para transportar um composto através da barreira hematoencefálica
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
LT3248600T (lt) * 2005-02-18 2020-07-27 Abraxis Bioscience, Llc Terapinių agentų deriniai bei įvedimo būdai ir kombinuotas gydymas
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
WO2006124737A2 (en) * 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
US8877714B2 (en) 2005-06-14 2014-11-04 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
BRPI0613005A8 (pt) * 2005-07-15 2017-12-26 Angiochem Inc uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos.
BRPI0615562A2 (pt) 2005-07-19 2010-01-26 Univ Illinois agentes de transporte para atravessamento da barreira sangue-cérebro e entrada nas células cancerìgenas do cérebro e métodos para o seu uso
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
CA2620585C (en) * 2005-08-31 2015-04-28 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
JP2009508494A (ja) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Crを含むタンパク質に対して特異的な受容体−結合タンパク質(rap)変異体を含む組成物およびその使用
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
WO2007053696A2 (en) * 2005-11-01 2007-05-10 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
EP2043696B1 (en) 2006-07-13 2015-02-25 Burnham Institute for Medical Research Methods and compositions for targeting gc1qr/p32
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US8487072B2 (en) * 2006-10-19 2013-07-16 Angiochem Inc. Compounds for stimulating P-glycoprotein function and uses thereof
US9399675B2 (en) 2007-02-28 2016-07-26 The Board Of Regents Of The University Of Oklahoma Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
KR101801454B1 (ko) 2007-03-21 2017-11-24 랩터 파마슈티컬스 인코포레이티드 환형의 수용체-연관된 단백질(rap) 펩티드
PL2164866T3 (pl) 2007-05-29 2014-10-31 Angiochem Inc Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek
WO2009039188A1 (en) * 2007-09-17 2009-03-26 Ludwig Institute For Cancer Research Ltd Peptides and methods for the treatment of gliomas and other cancers
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2011005963A (es) * 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
JP2012528596A (ja) 2009-06-03 2012-11-15 ダイセルナ ファーマシューティカルズ, インコーポレイテッド ペプチドダイサー基質剤およびその特異的な遺伝子発現阻害のための方法
PL2453923T3 (pl) 2009-07-14 2016-06-30 Mayo Found Medical Education & Res Niekowalencyjne dostarczanie aktywnych czynników przez barierę krew-mózg przy udziale peptydów
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
EP4201402A1 (en) 2010-03-08 2023-06-28 Sloan-Kettering Institute For Cancer Research Cdc7 kinase inhibitors and uses thereof
US9102697B2 (en) 2010-03-22 2015-08-11 President And Fellows Of Harvard College Trioxacarcins and uses thereof
WO2011119608A1 (en) 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
US8986689B2 (en) 2010-04-14 2015-03-24 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
US8218280B2 (en) 2010-07-08 2012-07-10 Schneider Electric USA, Inc. Secondary thermal sensor for primary conductors
US20120156130A1 (en) 2010-08-06 2012-06-21 Thore Hettmann Use of her3 binding agents in prostate treatment
CN102406949B (zh) 2010-09-21 2013-05-29 复旦大学 一种靶向示踪的多模式诊断纳米影像药物
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環化合物及びその使用
CA2817250A1 (en) 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
CN102552928A (zh) 2010-12-19 2012-07-11 复旦大学 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法
CA2824197C (en) 2011-01-10 2020-02-25 Michael Martin Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN102614105A (zh) 2011-01-28 2012-08-01 复旦大学 一种脑靶向载两性霉素b聚合物胶束给药系统
WO2012118376A1 (en) 2011-03-01 2012-09-07 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
DK2691443T3 (da) 2011-03-28 2021-05-03 Massachusetts Inst Technology Konjugerede lipomerer og anvendelser af disse
EP2696898A4 (en) 2011-04-07 2014-10-01 Univ Emory COMPOSITIONS COMPRISING SACCHARIDE BINDING FRACTIONS AND METHODS FOR TARGETED THERAPY
WO2013004716A1 (en) 2011-07-04 2013-01-10 Universität Basel Peptide beads
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
JP6078076B2 (ja) 2011-11-11 2017-02-08 インテリカイン, エルエルシー キナーゼ阻害剤多形体
US20150037311A1 (en) 2011-12-01 2015-02-05 Angiochem Inc. Targeted lysosomal enzyme compounds
SG11201403062YA (en) 2011-12-13 2014-07-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
WO2013120107A1 (en) 2012-02-09 2013-08-15 University Of Rochester Methods and compositions for treating a subject to inhibit hearing loss
WO2013131032A1 (en) 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Variants of prothymosin alpha and methods of using same

Also Published As

Publication number Publication date
JP2015157825A (ja) 2015-09-03
BRPI0910557A2 (pt) 2015-09-29
JP2011516587A (ja) 2011-05-26
WO2009127072A1 (en) 2009-10-22
TR201905480T4 (tr) 2019-05-21
US20110112036A1 (en) 2011-05-12
CN102026667A (zh) 2011-04-20
EP2279008A4 (en) 2013-09-04
MX355683B (es) 2018-04-26
AU2009238187A1 (en) 2009-10-22
US8710013B2 (en) 2014-04-29
CA2721019A1 (en) 2009-10-22
MX2010011339A (es) 2010-12-21
WO2009127072A8 (en) 2009-12-30
CA2721019C (en) 2015-09-15
EP2279008A1 (en) 2011-02-02
ZA201007170B (en) 2012-01-25
HK1154795A1 (en) 2012-05-04
CN102026667B (zh) 2014-06-25
RU2010146718A (ru) 2012-05-27
AU2009238187B2 (en) 2014-03-06
EP2279008B1 (en) 2019-03-06
RU2518240C2 (ru) 2014-06-10
PT2279008T (pt) 2019-05-20
JP5860698B2 (ja) 2016-02-16
DK2279008T3 (en) 2019-04-29
ES2721148T3 (es) 2019-07-29

Similar Documents

Publication Publication Date Title
HK1154795A1 (en) Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
HK1164050A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
IL214175A (en) Derivatives of aminotetralin, their pharmaceutical compositions and their use
ZA200900347B (en) Preparation of pharmaceutical compositions
IL195237A0 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
EP2447253A4 (en) DIHYDROPYRIMIDIN COMPOUNDS AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
IL212219A0 (en) Compositions comprising pyrone analogs and uses thereof
AP2920A (en) Anti-malarial pharmaceutical composition
EP2261221A4 (en) EPOTHILONE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR USE AND PREPARATIONS
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
EP2241569A4 (en) THIENOPYRIDAZINE COMPOUNDS, PREPARATIONS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USES
EP2320729A4 (en) GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
EP2386553A4 (en) BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
PT2504331E (pt) Composto, novas formas desse composto, composições farmacêuticas desse composto e métodos de preparação e utilização
IL213177A0 (en) Crystal forms, methods of preparation, pharmaceutical compositions and uses of nicousamide
IL210377A (en) History of Naphthyridone, their preparation and their pharmaceutical preparations
EP2296687A4 (en) PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN DOPAMINE CONJUGATES
PL2298090T3 (pl) Kompozycja farmaceutyczna lub nutraceutyczna
EP2358693A4 (en) PREPARATION OF DOCETAXEL
ZA201005316B (en) 2-amino-2-phenyl-alkanol derivatives, their preparation and pharmaceutical compositions containing them
EP2452681A4 (en) SALTS OF 13A- (S-) DESOXYTYLPHORININE, METHOD FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
ZA201003335B (en) Cephalomannine derivatives and their preparation,medicinal composition and use
ZA201200165B (en) 2-amino-2phenyl-alkanol derivatives, preparation thereof, and pharmaceutical compositions containing same
IL189408A0 (en) Siva3, its preparation and pharmaceutical compositions containing it